Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years.

Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH.

Retina. 2014 Aug;34(8):1531-8. doi: 10.1097/IAE.0000000000000134.

PMID:
24637667
2.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
3.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126
4.

Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol.

Berg K, Pedersen TR, Sandvik L, Bragadóttir R.

Ophthalmology. 2015 Jan;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041. Epub 2014 Sep 13.

PMID:
25227499
5.

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity.

Monés J, Biarnés M, Trindade F, Casaroli-Marano R.

Graefes Arch Clin Exp Ophthalmol. 2012 Dec;250(12):1737-44. doi: 10.1007/s00417-012-2009-5. Epub 2012 Apr 15.

6.

The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity.

Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.

Ophthalmology. 2014 May;121(5):1092-101. doi: 10.1016/j.ophtha.2013.11.031. Epub 2014 Jan 23.

7.

One-year outcomes of less frequent bevacizumab in age-related macular degeneration.

Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.

Retina. 2011 Apr;31(4):645-53. doi: 10.1097/IAE.0b013e3182012d18.

PMID:
21358363
8.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

9.

Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.

Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.

Retina. 2011 Oct;31(9):1812-8. doi: 10.1097/IAE.0b013e31821987a4.

PMID:
21866073
10.

Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC; Fight Retinal Blindness Study Group.

Ophthalmology. 2015 Jun;122(6):1212-9. doi: 10.1016/j.ophtha.2015.02.009. Epub 2015 Apr 4.

PMID:
25846847
11.

Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.

Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.

Ophthalmology. 2014 Jun;121(6):1237-45. doi: 10.1016/j.ophtha.2013.12.029. Epub 2014 Mar 28.

PMID:
24684838
12.

Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.

Giacomelli G, Giansanti F, Finocchio L, Biagini I, Bacherini D, Virgili G, Menchini U.

Retina. 2014 May;34(5):860-7. doi: 10.1097/IAE.0000000000000007.

PMID:
24756034
13.

Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.

El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF.

Retina. 2013 Oct;33(9):1828-35. doi: 10.1097/IAE.0b013e3182877a0d.

PMID:
23615342
14.

Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.

Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD.

Am J Ophthalmol. 2012 Mar;153(3):468-473.e1. doi: 10.1016/j.ajo.2011.08.011. Epub 2011 Oct 11.

PMID:
21996309
15.

Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration.

Lazzeri S, Figus M, Sartini MS, Scarinci F, Casini G, Guidi G, Cupo G, Cacciamani A, Fasanella V, Agnifili L, Piaggi P, Varano M, Ripandelli G, Nardi M, Parravano M.

Ophthalmologica. 2015;233(2):74-81. doi: 10.1159/000371393. Epub 2015 Jan 30.

PMID:
25662794
16.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
17.

Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration.

Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S.

Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):453-8. doi: 10.1007/s00417-012-2038-0. Epub 2012 May 11.

PMID:
22573410
18.

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group.

Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11.

19.

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Wykoff CC, Brown DM, Maldonado ME, Croft DE.

Br J Ophthalmol. 2014 Jul;98(7):951-5. doi: 10.1136/bjophthalmol-2013-304736. Epub 2014 Feb 11.

20.

A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.

Algvere PV, Steén B, Seregard S, Kvanta A.

Acta Ophthalmol. 2008 Aug;86(5):482-9. Epub 2007 Dec 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk